Authors
Latest:
Management of BCG-unresponsive NMIBC"An alternative off-label option for patients with BCG-unresponsive NMIBC is sequential intravesical gemcitabine and docetaxel (Gem/Doce)," write Rachel Passarelli, MD, and Vignesh T. Packiam, MD.
Latest:
Ellen Cahill, MD, on chaperone use for genitourinary exams"I think it would be really nice if we did have standardized guidelines on who could serve as a chaperone," says Ellen Cahill, MD.
Latest:
Legislation improves accessibility to mental health programs for cliniciansCongress has taken actions aimed at protecting arrangements in which hospitals and other entities provide bona fide mental health improvement, behavioral health improvement, or maintenance programs to physicians and other clinicians.
Latest:
Radium-223 is associated with low rates of AEs, treatment discontinuation for bone metastatic CRPCOf note, 55% of patients received a full course (6 injections) of radium-223 injections, and 67% received 5 of the 6 injections.
Latest:
Optimizing Multidisciplinary Care for BCG-Naive, High-Risk NMIBCPanelists discuss the characteristics of an ideal multidisciplinary team for managing BCG-naive, high-risk non–muscle-invasive bladder cancer (NMIBC), emphasizing the need for oncologists and urologists to collaboratively prepare for successful patient outcomes across different markets, while also identifying necessary educational resources and highlighting adverse events that require attention in preparation for product launches.
Latest:
Mayo study finds dietary habits that may help prevent kidney stones"Knowing the dietary factors that are most important for preventing kidney stone recurrence can help patients and providers know what to prioritize,” said Andrew Rule, MD.
Latest:
Management of recurrent prostate cancer after focal therapyProviders must carefully consider treatment options to align with patient preference.
Latest:
Survey highlights communication gaps with kidney cancer diagnosis and care“This indicates opportunities to improve communication about diagnosis, psychosocial impacts, and clinical trials, as well as biopsies, physical exercise, and patient engagement,” wrote Rachel H. Giles, PhD, and colleagues.
Latest:
Gary Steinberg, MD, on exploring novel combinations with bel-sar in NMIBC“There are a lot of other ways to look at bel-sar with other immunotherapy agents, other combinations, to truly help prevent patients needing to go to the operating room,” says Gary D. Steinberg, MD.
Latest:
Treatment Considerations for PSMA-Positive mCRPC PatientsNeal Shore, MD, FACS, highlights the exciting advancements in radioligand therapy for prostate cancer, noting that ongoing trials are exploring its use in various disease stages and settings, and emphasizes the importance of reviewing the VISION and FORE trial publications for further insights.
Latest:
Future Directions in PSMA-PET ImagingLooking to the future treatment landscape in prostate cancer, the panel provides closing thoughts on the trajectory of the utilization of PSMA-PET imaging and the unmet needs it might address.
Latest:
Financial toxicity is a growing concern in urologic oncology"Clinicians have opportunities to reduce patient subjective and objective financial burden if they continue to self-educate and communicate with patients and consider [financial toxicitiy] an adverse effect of treatment," write Alexandria A. Spellman, MD, MS, and Deborah R. Kaye, MD, MS.
Latest:
Future Directions in PSMA-PET ImagingLooking to the future treatment landscape in prostate cancer, the panel provides closing thoughts on the trajectory of the utilization of PSMA-PET imaging and the unmet needs it might address.
Latest:
13 tips to keep your patient data safe from hackersHere are 13 cybersecurity measures medical practices can take to protect patient data from hackers.
Latest:
PARP inhibitors: Treating mCRPC from a genetic basisTreatments provide a targeted therapeutic strategy for metastatic castration-resistant prostate cancer.
Latest:
Practice Management: Expert coding tipsA physician’s goal is to care for patients, but a key part of being able to provide that care is the eternal quest for payment.
Latest:
Managing BCG-Unresponsive NMIBC: Cretostimogene Monotherapy vs. Combination TherapyPanelists discuss their views on using cretostimogene as monotherapy versus combination therapy, the importance for urologists to stay updated on advances for managing BCG-unresponsive NMIBC, and the potential impact of combining cretostimogene with pembrolizumab on addressing unmet needs in NMIBC care.
Latest:
Upper tract urothelial carcinoma case illustrates rapidly changing treatment landscapeUrologists and medical oncologists should collaborate to tailor therapy to the specific needs of the patient.
Latest:
Management of recurrent prostate cancer after focal therapyProviders must carefully consider treatment options to align with patient preference.
Latest:
Expert robotic surgeon discusses da Vinci 5, advances in urologic surgery"It's actually a very exciting time to be a robotic surgeon," says Ronney Abaza, MD, FACS.
Latest:
Fertility preservation in patients with testicular cancer"Full discussion of the various fertility preservation options and an understanding of the fertility implications of the various treatment modalities must be understood by patients for them to make optimal decisions for their reproductive futures," write the authors.
Latest:
Urology Practice advice: Real estate pitfalls to avoidCommercial real estate can be one of the highest expenses for health care practices.
Latest:
Exciting Prospects for the Future of Localized Prostate Cancer TreatmentDr Mark Emberton shares what developments are visible on the horizon and what they represent for the future of focal therapy and treatment of clinically localized prostate cancer.
Latest:
Unmet Needs for the Treatment of Enteric HyperoxaluriaDr. Kyle Wood discusses optimal avenues to increase patient and provider education on enteric hyperoxaluria and provides closing thoughts on the future management of enteric hyperoxaluria.
Latest:
A Look Into The Future of PSMA-Targeted Therapies in Prostate CancerPanelists review the recent FDA approval of the PSMA-targeted therapy Lutetium Lu 177 vipivotide tetraxetan for patients with metastatic castration-resistant prostate cancer and discuss additional settings in which it, and other PSMA-targeted treatments, might be used in the future.
Latest:
Future Landscape of Prostate Cancer and Rectal SpacersThe expert panel concludes their discussion with a look toward the future of prostate cancer treatment and the evolving role of rectal spacers.
Latest:
BCG-unresponsive NMIBC: Current evidence and optionsMultiple investigational agents have been developed and are being studied.
Latest:
Future of Overactive Bladder TreatmentDrs MacDiarmid and Rogers discuss barriers to OAB treatments and therapies on the horizon.
Latest:
Managing Biochemical Recurrence in Prostate Cancer: Risk Stratification and Treatment DecisionsPanelists discuss how management options for nonmetastatic castration-sensitive prostate cancer (nmCSPC) include active surveillance, radiotherapy, and systemic therapy, with recommendations influenced by factors such as tumor volume, prostate-specific antigen (PSA) doubling time, and patient life expectancy, particularly for those with high-volume symptomatic disease.
Latest:
A primer on DNA sequencing for the practicing urologistEmbracing and understanding new and emerging molecular techniques will improve patient outcomes.
